Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept studyPeter Connick, Siddharthan Chandran, Rickie Patani et al.|The Lancet Neurology|2012Cited by 606
Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosisGiulia E. Tyzack, Rickie Patani|Brain|2019Cited by 191
Intron retention and nuclear loss of SFPQ are molecular hallmarks of ALSRaphaëlle Luisier, Rickie Patani|Nature Communications|2018Cited by 169
The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessmentsPeter Connick, Siddharthan Chandran, Madhan Kolappan et al.|Trials|2011Cited by 119